(NASDAQ: SLNO) Soleno Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.89%.
Soleno Therapeutics's revenue in 2024 is $0.On average, 4 Wall Street analysts forecast SLNO's revenue for 2025 to be $1,038,299,147, with the lowest SLNO revenue forecast at $674,810,872, and the highest SLNO revenue forecast at $1,426,587,500. On average, 3 Wall Street analysts forecast SLNO's revenue for 2026 to be $4,719,788,943, with the lowest SLNO revenue forecast at $1,285,094,898, and the highest SLNO revenue forecast at $8,450,684,536.
In 2027, SLNO is forecast to generate $8,661,562,933 in revenue, with the lowest revenue forecast at $2,108,783,975 and the highest revenue forecast at $15,214,341,892.